The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
The Japan Pharmaceutical Manufacturers Association (JPMA) welcomes a recently enacted amendment of the next-generation medical infrastructure law, which creates a new category of information called “pseudonymized medical data.” Such data will drive drug discoveries in the rare disease space, the…
To read the full story
Related Article
- AZ Wins Certification to Allow Use of Pseudonymized Medical Info
March 6, 2025
- JPMA Calls for Legal Framework to Facilitate Use of Pseudonymized Data
November 27, 2024
- Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
- Legal Changes Needed to Push Use of Pseudonymized Data in Drug R&D: MHLW Working Group
January 16, 2024
ORGANIZATION
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…